1. Tumour infiltrating lymphocytes and survival after adjuvant chemotherapy in patients with gastric cancer: post-hoc analysis of the CLASSIC trial
- Author
-
Drolaiz H. W. Liu, Young-Woo Kim, Nina Sefcovicova, Jon P. Laye, Lindsay C. Hewitt, Andrew F. Irvine, Vincent Vromen, Yannick Janssen, Naser Davarzani, Gregorio E. Fazzi, Shahab Jolani, Veerle Melotte, Derek R. Magee, Myeong-Cherl Kook, Hyunki Kim, Rupert Langer, Jae-Ho Cheong, Heike I. Grabsch, and Clinical Genetics
- Subjects
PROGNOSTIC VALUE ,Cancer Research ,OUTCOMES ,Oncology ,SDG 3 - Good Health and Well-being ,S-1 ,CAPECITABINE ,OXALIPLATIN ,OPEN-LABEL - Abstract
Background: Only a subset of gastric cancer (GC) patients with stage II–III benefits from chemotherapy after surgery. Tumour infiltrating lymphocytes per area (TIL density) has been suggested as a potential predictive biomarker of chemotherapy benefit. Methods: We quantified TIL density in digital images of haematoxylin-eosin (HE) stained tissue using deep learning in 307 GC patients of the Yonsei Cancer Center (YCC) (193 surgery+adjuvant chemotherapy [S + C], 114 surgery alone [S]) and 629 CLASSIC trial GC patients (325 S + C and 304 S). The relationship between TIL density, disease-free survival (DFS) and clinicopathological variables was analysed. Results: YCC S patients and CLASSIC S patients with high TIL density had longer DFS than S patients with low TIL density (P = 0.007 and P = 0.013, respectively). Furthermore, CLASSIC patients with low TIL density had longer DFS if treated with S + C compared to S (P = 0.003). No significant relationship of TIL density with other clinicopathological variables was found. Conclusion: This is the first study to suggest TIL density automatically quantified in routine HE stained tissue sections as a novel, clinically useful biomarker to identify stage II–III GC patients deriving benefit from adjuvant chemotherapy. Validation of our results in a prospective study is warranted.
- Published
- 2023